C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism

2003 ◽  
Vol 285 (4) ◽  
pp. E864-E870 ◽  
Author(s):  
Bo-Lennart Johansson ◽  
John Wahren ◽  
John Pernow
Keyword(s):  
Nitric Oxide ◽  
Blood Flow ◽  
Forearm Blood Flow ◽  
Muscle Blood Flow ◽  
Underlying Mechanism ◽  
Saline Infusion ◽  
Diabetic Patients ◽  
C Peptide ◽  
Type 1 Diabetic Patients

Proinsulin C-peptide has been shown to increase muscle blood flow in type 1 diabetic patients. The underlying mechanism is not fully understood. The aim of this study was to evaluate if the vasodilator effect of C-peptide is mediated by nitric oxide (NO). Eleven type 1 diabetic patients were studied two times and randomized to administration of intravenous and intra-arterial infusion of C-peptide or saline. Forearm blood flow (FBF) was measured by venous occlusion plethysmography during infusion of C-peptide or saline before, during, and after NO synthase (NOS) blockade. Endothelium-dependent and -independent vasodilatation was evaluated by administration of acetylcholine and sodium nitroprusside, respectively. FBF increased by 35% during intravenous C-peptide ( P < 0.01) but not during saline infusion (–2%, not significant). NOS blockade resulted in a more pronounced reduction in FBF during intravenous C-peptide than during saline infusion (–41 vs. –26%, P < 0.05). Intra-arterial C-peptide failed to increase FBF during NOS blockade. However, when C-peptide was given after the recovery from NOS blockade, FBF rose by 30% ( P < 0.001). The vasodilator effects of acetylcholine and nitroprusside were not influenced by C-peptide. It is concluded that the stimulatory effect of C-peptide on FBF in type 1 diabetic patients is mediated via the NO system and that C-peptide increases basal endothelial NO levels.

C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients

2004 ◽  
Vol 286 (1) ◽  
pp. E14-E19 ◽  
Author(s):  
Bo-Lennart Johansson ◽  
Jan Sundell ◽  
Karin Ekberg ◽  
Cathrine Jonsson ◽  
Marko Seppänen ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Blood Flow ◽  
Type 1 Diabetes ◽  
Muscle Blood Flow ◽  
Left Ventricular ◽  
Diabetic Patients ◽  
Skeletal Muscle Blood Flow ◽  
C Peptide ◽  
Type 1 Diabetic Patients

Patients with type 1 (insulin-dependent) diabetes show reduced skeletal muscle blood flow and coronary vasodilatory function despite intensive insulin therapy and good metabolic control. Administration of proinsulin C-peptide increases skeletal muscle blood flow in these patients, but a possible influence of C-peptide on myocardial vasodilatory function in type 1 diabetes has not been investigated. Ten otherwise healthy young male type 1 diabetic patients (Hb A1c 6.6%, range 5.7-7.9%) were studied on two consecutive days during normoinsulinemia and euglycemia in a double-blind, randomized, crossover design, receiving intravenous infusion of C-peptide (5 pmol·kg-1·min-1) for 120 min on one day and saline infusion on the other day. Myocardial blood flow (MBF) was measured at rest and during adenosine administration (140 μg·kg-1·min-1) both before and during the C-peptide or saline infusions by use of positron emission tomography and [15O]H2O administration. Basal MBF was not significantly different in the patients compared with an age-matched control group, but adenosine-induced myocardial vasodilation was 30% lower ( P < 0.05) in the patients. During C-peptide administration, adenosine-stimulated MBF increased on average 35% more than during saline infusion ( P < 0.02) and reached values similar to those for the healthy controls. Moreover, as evaluated from transthoracal echocardiographic measurements, C-peptide infusion resulted in significant increases in both left ventricular ejection fraction (+5%, P < 0.05) and stroke volume (+7%, P < 0.05). It is concluded that short-term C-peptide infusion in physiological amounts increases the hyperemic MBF and left-ventricular function in type 1 diabetic patients.

scholarly journals Effects of C-peptide on Microvascular Blood Flow and Blood Hemorheology

2004 ◽  
Vol 5 (1) ◽  
pp. 51-64 ◽  
Author(s):  
T. Forst ◽  
T. Kunt
Keyword(s):  
Blood Flow ◽  
Atpase Activity ◽  
Cell Types ◽  
Erythrocyte Deformability ◽  
Microvascular Blood Flow ◽  
Diabetic Patients ◽  
C Peptide ◽  
Rheologic Properties ◽  
Type 1 Diabetic Patients

Beside functional and structural changes in vascular biology, alterations in the rheologic properties of blood cells mainly determines to an impaired microvascular blood flow in patients suffering from diabetes mellitus. Recent investigations provide increasing evidence that impaired C-peptide secretion in type 1 diabetic patients might contribute to the development of microvascular complications. C-peptide has been shown to stimulate endothelial NO secretion by activation of theCa2+calmodolin regulated enzyme eNOS. NO himself has the potency to increase cGMP levels in smooth muscle cells and to activateNa+K+ATPase activity and therefore evolves numerous effects in microvascular regulation. In type 1 diabetic patients, supplementation of C-peptide was shown to improve endothelium dependent vasodilatation in an NO-dependent pathway in different vascular compartments. In addition, it could be shown that C-peptide administration in type 1 diabetic patients, results in a redistribution of skin blood flow by increasing nutritive capillary blood flow in favour to subpapillary blood flow. ImpairedNa+K+ATPase in another feature of diabetes mellitus in many cell types and is believed to be a pivotal regulator of various cell functions. C-peptide supplementation has been shown to restoreNa+K+ATPase activity in different cell types during in vitro and in vivo investigations. In type 1 diabetic patients, C-peptide supplementation was shown to increase erythrocyteNa+K+ATPase activity by about 100%. There was found a linear relationship between plasma C-peptide levels and erythrocyteNa+K+ATPase activity. In small capillaries, microvascular blood flow is increasingly determined by the rheologic properties of erythrocytes. Using laser-diffractoscopie a huge improvement in erythrocyte deformability could be observed after C-peptide administration in erythrocytes of type 1 diabetic patients. Inhibition of theNa+K+ATPase by Obain completely abolished the effect of C-peptide on erythrocyte deformability. In conclusion, C-peptide improves microvascular function and blood flow in type 1 diabetic patients by interfering with vascular and rheological components of microvascular blood flow.

Decreased distensibility of resistance vessels of the skin in type 1 (insulin-dependent) diabetic patients with microangiopathy

1987 ◽  
Vol 72 (1) ◽  
pp. 123-130 ◽  
Author(s):  
J. Kastrup ◽  
T. Nørgaard ◽  
H.-H. Parving ◽  
N. A. Lassen
Keyword(s):  
Blood Flow ◽  
Inverse Correlation ◽  
Diabetic Patients ◽  
Resistance Vessels ◽  
Head Up Tilt ◽  
Insulin Dependent ◽  
Insulin Dependent Diabetic ◽  
Type 1 Diabetic Patients ◽  
Term Type

1. The distensibility of the resistance vessels of the skin at the dorsum of the foot was determined in 11 long-term type 1 (insulin-dependent) diabetic patients with nephropathy and retinopathy, nine short-term type 1 diabetic patients without clinical microangiopathy and in nine healthy non-diabetic subjects. 2. Blood flow was measured by the local 133Xexenon washout technique in a vascular bed locally paralysed by the injection of histamine. Blood flow was measured before, during and after a 40 mmHg increase of the vascular transmural pressure, induced by head-up tilt. 3. The mean increase in blood flow during headup tilt was only 24% in diabetic subjects with and 48% in diabetic patients without clinical microangiopathy, compared with 79% in normal non-diabetic subjects (P < 0.0005 and P < 0.05, respectively). 4. An inverse correlation between microvascular distensibility and degree of hyalinosis of the terminal arterioles in biopsies from the skin was demonstrated (r = − 0.57, P < 0.001). 5. Our results suggest that terminal arteriolar hyalinosis reduces the microvascular distensibility and probably increases the minimal vascular resistance, thereby impeding hyperaemic responses.

Blood flow in the skin of type 1 diabetic patients before and after combined pancreas/kidney transplantation

2005 ◽  
Vol 21 (6) ◽  
pp. 525-532 ◽  
Author(s):  
Nicola Eberl ◽  
Wolfgang Piehlmeier ◽  
Stefan Dachauer ◽  
August König ◽  
Walter Land ◽  
...  
Keyword(s):  
Blood Flow ◽  
Kidney Transplantation ◽  
Diabetic Patients ◽  
Before And After ◽  
Pancreas Kidney Transplantation ◽  
Type 1 Diabetic Patients

scholarly journals Retinal Blood Flow in Type 1 Diabetic Patients With No or Mild Diabetic Retinopathy During Euglycemic Clamp

Diabetes Care ◽  
2010 ◽  
Vol 33 (9) ◽  
pp. 2038-2042 ◽  
Author(s):  
B. Pemp ◽  
E. Polska ◽  
G. Garhofer ◽  
M. Bayerle-Eder ◽  
A. Kautzky-Willer ◽  
...  
Keyword(s):  
Blood Flow ◽  
Diabetic Retinopathy ◽  
Retinal Blood Flow ◽  
Diabetic Patients ◽  
Euglycemic Clamp ◽  
Type 1 Diabetic Patients

scholarly journals Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients

2010 ◽  
Vol 24 (4) ◽  
pp. 875-875
Author(s):  
Urd Kielgast ◽  
Meena Asmar ◽  
Sten Madsbad ◽  
Jens J. Holst
Keyword(s):  
Insulin Secretion ◽  
Cell Function ◽  
Glucagon Secretion ◽  
Diabetic Patients ◽  
Β Cell ◽  
C Peptide ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Type 1 Diabetic Patients

Abstract Context: The mechanism by which glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion is uncertain, and it is not determined whether endogenous insulin is a necessary factor for this effect. Objective: Our objective was to characterize the α- and β-cell responses to GLP-1 in type 1 diabetic patients without residual β-cell function. Methods: Nine type 1 diabetic patients, classified as C-peptide negative by a glucagon test, were clamped at plasma glucose of 20 mmol/liter for 90 min with arginine infusion at time 45 min and concomitant infusion of GLP-1 (1.2 pmol/kg · min) or saline. Results: Infusion with GLP-1 increased C-peptide concentration just above the detection limit of 33 pmol/liter in one patient, but C-peptide remained immeasurable in all other patients. In the eight remaining patients, total area under the curve of glucagon was significantly decreased with GLP-1 compared with saline: 485 ± 72 vs. 760 ± 97 pmol/liter · min (P &lt; 0.001). In addition, GLP-1 decreased the arginine-stimulated glucagon release (incremental AUC of 103 ± 21 and 137 ± 16 pmol/liter · min, with GLP-1 and saline, respectively, P &lt; 0.05). Conclusions: In type 1 diabetic patients without endogenous insulin secretion, GLP-1 decreases the glucagon secretion as well as the arginine-induced glucagon response during hyperglycemia. GLP-1 induced endogenous insulin secretion in one of nine type 1 diabetic patients previously classified as being without endogenous insulin secretion.

Sign in / Sign up

Export Citation Format

Share Document